Journal ArticleDOI
4. Modelling Survival Data in Medical Research
About:
This article is published in Journal of The Royal Statistical Society Series A-statistics in Society.The article was published on 1995-01-01. It has received 1092 citations till now. The article focuses on the topics: Medical research.read more
Citations
More filters
Journal ArticleDOI
Analysing censored data using Kaplan-Meier methods; survival analysis.
TL;DR: Survival analysis techniques must be used that take account of this censoring in both situations described here.
Journal ArticleDOI
Determination and study of lead times of metallic components in the aerospace industry through a Cox-type hazard model
FranciscoJavier De Cos Juez,FernandoSánchez Lasheras,AnaSuárez Sánchez,PedroRiesgo Fernández,Paulino-José García Nieto +4 more
TL;DR: This article employs Cox-type hazard models, which are a well-recognized statistical technique for exploring the relationship between a time variable, in this case the lead time, and several explanatory variables (covariates).
Book ChapterDOI
Transition from University to the Job Market. A Time Analysis of the University of Cagliari Graduates
Mariano Porcu,Nicola Tedesco +1 more
TL;DR: An analysis of determinants of the period that elapses between graduation and finding work is performed by means of non-parametric and parametric survival models.
Survival modelling and analysis of HIV/AIDS patients on HIV care and antiretroviral treatment to determine longevity prognostic factors
TL;DR: The conceptual framework and objectives of the study are summarized, and the likelihood function for the proportional hazards modelling (PHM) is explained.
Improving statistical analysis of prospective clinical trials in stem cell transplantation. An inventory of new approaches in survival analysis
TL;DR: The initial task was to create an inventory of the existing biostatistical literature on new approaches to survival analyses that were not currently widely utilised, and the estimation of survival endpoints is introduced, with an emphasis on recent developments which complements standard analysis.
References
More filters
Journal ArticleDOI
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Geoffrey A. Block,Preston S. Klassen,J. Michael Lazarus,Norma J. Ofsthun,Edmund G. Lowrie,Glenn M. Chertow +5 more
TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
TL;DR: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more.